Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.other||Faculty of Medicine, Siriraj Hospital, Mahidol University||en_US|
|dc.identifier.citation||Pharmaceutical Sciences Asia. Vol.45, No.4 (2018), 252-262||en_US|
|dc.description.abstract||© Faculty of Pharmacy, Mahidol University (Thailand) 2018. A highly selective, sensitive and reproducible liquid chromatography tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of losartan and its active metabolite (EXP3174) in human plasma, using candesartan as an internal standard (IS), was described. Chromatographic separation was carried out in the Luna HST 2.5μm C18 (50×3 mm.). The mobile phases were 0.05% formic acid and acetonitrile at a ratio of 3.3:6.7 (v/v). The mass spectrometry was operated in positive electrospray ionization and multiple reactions monitoring (MRM) mode. Liquid-liquid extraction (LLE) was employed with the mixture of ethylacetate and hexane at a ratio of 9:1 (v/v). The method was developed and fully validated according to the USFDA guidance. The limit of detection (LOD) of losartan and EXP3174 were 0.10 and 0.20 ng/mL, respectively and the lower limit of quantification (LLOQ) of both losartan and EXP3174 were 0.5 ng/mL. This method demonstrated good linearity (r 2 > 0.999) ranged from 0.5-2,500 ng/mL for both losartan and EXP3174. Accuracy and precision of the method were acceptable with high recovery of extraction. Neither anticoagulant nor matrix affected the analysis. This method was successfully applied to determine the concentrations of losartan and EXP3174 in human plasma in a bioequivalence study.||en_US|
|dc.subject||Pharmacology, Toxicology and Pharmaceutics||en_US|
|dc.title||Liquid chromatography tandem mass spectrometry method for simultaneous determination of losartan and its active metabolite in human plasma||en_US|
|Appears in Collections:||Scopus 2018|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.